Blog

DEEP RESEARCH · CHINESE BIOTECH

Chinese Biotech: Licensing Surge and Global R&D Rewiring

NMPA acceleration, Big Pharma patent cliffs, and the ADC, obesity, and CAR-T pipeline shift.

Date: 2025-11-26 · Biotech/licensing analysis · Naver Blog

Investment decisions are your responsibility. This material is research, not a recommendation to buy or sell.

0. Bottom line first

I no longer see Chinese biotech as merely a generic manufacturing base. The core 2024-2025 shift is that Chinese companies have become innovation suppliers filling Big Pharmas pipeline gaps.

Re-rating Chinese biotechFrom fast follower to first-in-class candidate
RegulationNMPA 30-day IND
DemandBig Pharma patent cliff
TechnologyADC, GLP-1, CAR-T
CapitalNewCo/licensing
Policy, global demand, and modality innovation are converging.

1. Growth backdrop

Official fact: The source says NMPA/CDE proposed and expanded a pilot to shorten innovative-drug clinical trial review from 60 working days to 30 days.

ItemOld systemNew systemImplication
Review methodApproval notice requiredImplied approval if no objectionLower administrative uncertainty
ScopeAll INDsInnovative, pediatric, rare-disease, and global co-development drugsPriority for high-value R&D
Timeline60 days30 daysFaster MRCT participation

Interpretation: Big Pharma patent cliffs and weaker internal R&D productivity form the demand-side reason for Chinese out-licensing. Faster regulation and external pipeline demand rose together.

2. Key companies and deals

Hengrui

Jiangsu Hengrui

Partnerships with Merck KGaA, MSD, and GSK show the shift into oncology, metabolic, respiratory, and immunology innovation.

Innovent

Innovent

Mazdutide, a GLP-1/GCG dual agonist, represents Chinese competitiveness in obesity and metabolic disease.

ADC

Kelun and Hansoh

Kelun is framed as an MSD ADC partner, while Hansoh is gaining visibility in B7-family ADCs.

Global

BeiGene and Legend

BeiGene shows hematology commercialization, while Legend is presented as a global CAR-T standard candidate.

3. Modality meaning

  • ADC: antibody selectivity, linker stability, and payload design are core out-licensing assets.
  • GLP-1/obesity: mazdutide and the Eccogene-AstraZeneca collaboration show China can supply metabolic-disease pipelines.
  • CAR-T: Legend Biotechs commercialization experience shows a Chinese platform can expand into global approval and manufacturing.

4. Risks and conclusion

  • US-China geopolitics, BIOSECURE-style debates, and data-verification concerns remain discount factors.
  • Deal values have grown, but clinical failure, returned rights, and commercialization delays remain possible.
  • NewCo structures can improve capital efficiency, but rights ownership and shareholder value capture need scrutiny.

The frame has shifted from low-cost production to global R&D supply. I would track Hengrui, Innovent, Kelun/Hansoh, and BeiGene/Legend as modality representatives.

Sources

Naver original